Growth Options, Equity Risk and Returns: Evidence from Pharmaceutical and Biotechnology Firms

Posted: 11 Jun 2015 Last revised: 6 Apr 2022

See all articles by Azizjon Alimov

Azizjon Alimov

IESEG School of Management LEM-CNRS UMR 9221

Date Written: Novermber 1 2015 ,

Abstract

Real options models predict that the creation and exercise of growth options are important determinants of firm equity risk and expected returns. This paper tests these predictions by examining risk and return dynamics around approvals of highly-innovative drugs and awards of patents underlying these drugs. Both events are associated with significant short and medium-term increases in stock prices, the magnitude of which is positively related to the value of embedded growth options. The systematic and idiosyncratic risk increases following patent awards and the idiosyncratic risk decreases following drug approvals. However, equity risk changes are not systematically related to subsequent stock prices changes.

Keywords: Real Options, Expected Returns, Dynamic Risk, Idiosyncratic Risk, Announcement Effects

JEL Classification: G31, G32

Suggested Citation

Alimov, Azizjon, Growth Options, Equity Risk and Returns: Evidence from Pharmaceutical and Biotechnology Firms (Novermber 1 2015 ,). Available at SSRN: https://ssrn.com/abstract=1100180 or http://dx.doi.org/10.2139/ssrn.1100180

Azizjon Alimov (Contact Author)

IESEG School of Management LEM-CNRS UMR 9221 ( email )

1 Parvis de La Défense
Paris, 92044
France

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
603
PlumX Metrics